活动家投资者Starboard Value批评瑞公司管理层研发表现不佳,并过度支付收购费用,导致自2021年以来股票下跌50%. Activist investor Starboard Value criticizes Pfizer's management for poor R&D performance and overpaying for acquisitions, leading to a 50% stock decline since 2021.
激进投资者 Starboard Value 批评辉瑞的管理层在研发 （R&D） 方面表现不佳，并为收购支付过高的费用，导致自 2021 年以来股价下跌了 50%。 Activist investor Starboard Value has criticized Pfizer's management for poor performance in research and development (R&D) and overpaying for acquisitions, leading to a 50% stock decline since 2021. 尽管从COVID-19增加400亿美元,但Pfizer自2019年以来市场价值损失200亿美元。 Despite a $40 billion boost from COVID-19, Pfizer lost $20 billion in market value since 2019. Starboard 认为辉瑞的预期研发和并购投资回报仅为 15%，远低于 38% 的行业中位数，并呼吁董事会追究管理层的责任。 Starboard argues that Pfizer’s expected return on R&D and M&A investments is only 15%, significantly below the industry median of 38%, and calls for the board to hold management accountable.